Resomelagon (AP1189)
Rheumatoid Arthritis (newly diagnosed, high disease activity)
Key Facts
About SynAct Pharma
SynAct Pharma is pioneering a resolution therapy approach to inflammation, moving beyond traditional immunosuppression. Its lead asset, resomelagon, is a first-in-class, biased agonist of melanocortin receptors 1 and 3, currently in Phase 2b development for rheumatoid arthritis and Phase 2 for Dengue fever. The company's strategy aims to create a new standard of care across a wide inflammatory disease spectrum by promoting the body's natural healing processes. With a pipeline that includes an injectable peptide candidate, SynAct is positioning itself at the forefront of a novel therapeutic paradigm.
View full company profileAbout SynAct Pharma
SynAct Pharma is pioneering a resolution therapy approach to inflammation, moving beyond traditional immunosuppression. Its lead asset, resomelagon, is a first-in-class, biased agonist of melanocortin receptors 1 and 3, currently in Phase 2b development for rheumatoid arthritis and Phase 2 for Dengue fever. The company's strategy aims to create a new standard of care across a wide inflammatory disease spectrum by promoting the body's natural healing processes. With a pipeline that includes an injectable peptide candidate, SynAct is positioning itself at the forefront of a novel therapeutic paradigm.
View full company profile